WebNov 4, 2024 · SignalChem’s latest clinical program, the protein kinase AXL Inhibitor SLC-391 for cancer therapy, is set to act as a critical inhibitor for cancer cell growth and metastasis. AXL is believed to play key roles in cancer cell survival, angiogenesis, metastasis and therapeutic resistance, as well as anti-tumour immunity suppression. WebMay 5, 2024 · 110-13120 Vanier Place. Richmond. British Columbia, V6V 2J2. Canada. Phone: 1 604 2324600. Visit Website Request Information/Quote Download PDF Copy.
PhosphoSens Sensor Peptides for Continuous Kinase Assays
WebMar 23, 2024 · VANCOUVER, BRITISH COLUMBIA – March 23, 2024 – Life Science Newswire – SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a … WebSignalChem Lifesciences Corporation is a company engaged in bioreagent development and drug discovery processes. It focuses on producing diagnostic kits and molecule kinase inhibitors for the treatment of human diseases including cancer. Type Private Status Active Founded 2004 HQ e88 r2-series bobcat compact excavator
SignalChem
WebSignalChem Lifesciences Corporation (SLC) 147 followers on LinkedIn. Drug discovery focused on developing novel small molecule kinase inhibitors for the treatment of cancer Headquartered in British Columbia, Canada, SignalChem was established in 2004 and became a global leader in cell signaling and protein engineering. The company employs … WebTo place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: [email protected] www.signalchem.com FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS. SAFETY DATA SHEET Article 1 - Product Identification Product Name: PI3K (p110d/p85a), Active Catalog # P30 … e88 body temperature smart watch